Once-Daily Sustained-Release Matrix Tablets of Metoprolol Tartrate : Formulation and In-vitro Evaluation by Hiremath S N et al.
Indian J.Pharm. Educ. Res. 44(1), Jan-Mar, 2010
Once-Daily Sustained-Release Matrix Tablets of  Metoprolol 
Tartrate : Formulation and In-vitro Evaluation
*1 2 3 4   Hiremath S.N. , Patil  S.D ., Swamy P.V . and Md.Younus Ali
  1Pravara  RES College of Pharmacy, Chincholi, Nashik-422101, Maharastra (India).
     2Research Associate, Glenmark Pharmaceuticals Ltd, Sinnar, 
     Nashik-422113, Maharastra (India).
  3,4Department of Pharmaceutics, H.K.E. Society's College of Pharmacy,  Sedam Road,    
     Gulbarga-585 105. Karnataka (India).
* For Correspondence: snhiremath@rediffmail.com
Abstract
The purpose of the present work was to design and evaluate the once daily sustained release matrix tablets of 
metoprolol tartrate based on hydrophilic matrices of hydroxypropyl methyl cellulose (HPMC) of different viscosity 
grades (Methocel K4M, K15M and K100M) and Carbopol-940. The compressed matrix tablets were evaluated for 
various parameters like hardness, friability, weight variation, drug content uniformity, drug-polymer interaction and 
in-vitro drug release studies. In-vitro drug release studies were performed in pH 6.8 phosphate buffer using USP 
apparatus-II (paddle) at 50 rpm.  The drug release rate from higher viscosity grade matrices was slower when 
compared to lower viscosity grades.  Increase in drug-polymer ratio from 1:1 to 1:3 resulted in decreased release of 
metoprolol tartrate. Inclusion of Carbopol-940 in tablets along with HPMC resulted in a further reduction in the drug 
release rate.  Formulation containing drug-polymer ratio (1:3) with the combination of HPMC  and Carbopol as 
matrix material showed promising results and release approximately 90% of metoprolol tartrate in 20 hours. The 
drug release mechanism was predominantly found to be non-Fickian (anomalous) diffusion controlled. Release 
profile also showed a tendency to follow near zero-order kinetics. The results of this study provided the framework for 
further work involving both in-vivo studies and scale-up .
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INTRODUCTION
The purpose of  this study was to design and evaluate 
once daily sustained release matrix tablets of metoprolol 
tartrate using various grades of HPMC as matrix material. 
Metoprolol tartrate is  selective -adrenoreceptor 1
blocking agent used in the treatment of various 
1-2cardiovascular disorders and prophylaxis of migraine .  
It has been classified as a class I substance according to 
the Biopharmaceutics Classification Scheme (BCS), 
meaning that it is highly soluble and highly permeable. 
The drug is readily and completely absorbed throughout 
the  whole intestinal  tract but is subject to extensive first 
pass metabolism resulting in incomplete bioavailability 
(about 50%). After a single oral dose, peak plasma 
concentrations occur after about 1-2 hours. The drug is 
eliminated within 3 to 4 hours, which, depending on 
therapeutic intention, makes it necessary to administer 
simple formulations of Metoprolol tartrate up to 4 times 
daily. Based on these properties and the well-defined 
relationship between the beta blocking effect and plasma 
drug  concentration,  Metoprolol  tartrate  lends  itself  to 
an sustained-release  (SR) formulation. Metoprolol 
tartrate SR formulations smooth out peaks and valleys in 
theplasma levels and enable less frequent dosing. Dosing 
3intervals are typically reduced to  once or twice a day .
In the present work hydrophilic polymers such as 
carbomers (carbopol-940) and cellulose derivatives such 
as HPMC of various grades have been used as release 
retarding agents. Cellulose derivatives have been widely 
used in the formulation of hydrogel matrices for 
controlled drug delivery. Among them, HPMC is the 
most extensively utilized because of its ease of use, 
availability and very low toxicity. Carbomers and HPMC 
are hydrophilic polymers with high gelling capacities.  
When these polymers comes in contact with  water it 
undergoes  rapid hydration of the macromolecules in the 
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solid-liquid interface followed by formation of a viscous 
layer.  The matrix system produced as a result of this 
process can pass along the gastrointestinal tract without 
breaking up and releasing the active ingredient 
4progressively .
MATERIALS AND METHODS
Metoprolol tartrate and Cellactose were gift samples 
from Astra-Zeneca Pharma India Limited., Bangalore 
and Anglo-French, Bangalore respectively.  HPMC 
(Methocel K4M, K15M and K100M) procured 
commercially from Colorcon India Private Limited, Goa.  
Carbopol-940, magnesium stearate and talc are obtained 
from S.d Fine Chemicals Limited, Mumbai.
Preparation of Matrix Tablets
The sustained release matrix tablet formulation consisted 
of a drug, polymer and diluent.  The ratios of the drug and 
polymer were maintained at 1:1, 1:2 and 1:3 levels, while 
diluent content was varied. The composition of various 
tablet formulations are given in Table-1. The drug, 
polymer and diluents were passed through a 100-mesh 
sieve and thoroughly mixed in a glass mortar for 15 
minutes. The lubricant and glidants were added to the 
previous mixture and again mixed for 5 minutes. Then the 
tablets were directly compressed using a Cadmach Single 
Punch Tablet Machine. The compressed tablets were 
evaluated for physical parameters such as weight 
uniformity, hardness, friability, drug content uniformity 
and in vitro release pattern.
Drug Content Uniformity
Five tablets were powdered in a mortar, from this powder 
equivalent to 50 mg of drug was taken in a 100 ml round 
bottom flask.  It was extracted by shaking with two 
successive 10 ml portions of methanol for 15 min each, 
filtered in a 25 ml volumetric flask and the filtrate was 
made up to the mark with methanol.  Further appropriate 
dilutions were made and the absorbance was measured at 
276  nm us ing  a  Sh imadzu  1700  UV/Vis  
spectrophotometer against methanol blank.
5, 6In-vitro Drug Release Studies 
In vitro dissolution studies of metoprolol tartrate tablets 
were carried out in USP XXIII tablet dissolution test 
apparatus-II (Electrolab) employing a paddle stirrer 
rotating at 50 rpm, 900 ml of pH 6.8 phosphate buffer was 
used as a dissolution medium.  The temperature of the 
dissolution medium was maintained at 37±0.5 ºC 
throughout the experiment.  One tablet was used in each 
test, 5 ml sample of dissolution medium was withdrawn 
by means of a syringe fitted with a prefilter at specified 
intervals of time and was immediately replaced with 
fresh medium.  The sample was analyzed for drug release 
by measuring the absorbance at 274.2 nm using UV-
Visible spectrophotometer after suitable dilution.
Drug-Excipient Interaction  study
There is always possibility of drug-excipient interaction  
in any formulation due to there intimate contact. The 
drug-excipient  interaction studies were  carried out by 
employing  IR  spectrocopic technique, which is one of 
the most powerful  analytical techniques that offers 
possibility of chemical identification. The IR spectrum of 
metoprolol tartrate, cellactose, HPMC (K100 M), 
carbopol 940 and formulation  F10 were obtained by KBr  
pellet method .
RESULTS AND DISCUSSION
The prepared matrix tablets were evaluated  for 
parameters such as hardness, weight variation, friability, 
drug content uniformity and were found to be in the range 
of 5.60±0.59 to 5.90±0.37, 199±0.87 to 254±1.46,0.59 to 
0.67, 96.32±1.41 to 99.72±.052 respectively  (Table-2).
IR spectroscopy was used as a means of studying drug-
excipient interaction. The IR spectrum of metoprolol 
-1tartrate exhibits peak at 1162.7 cm  is due to ether 
-1linkage, peak at 3693.9 cm  is due to (-OH-) linkage and 
-1peak at  2981.1 cm  is due to secondary amine (-NH-) 
confirm the structure of the drug. The IR spectrum of  F10 
-1formulation exhibited peak at 1167.7 cm  is due to ether 
-1linkage, peak at 3694.8 cm  is due to (-OH-) linkage and 
-1peak at 2926.5 cm  is due to secondary amine (-NH-). 
The presence of all the above peaks in the formulation 
confirms undisturbed structure of metoprolol tartrate and 
there was no drug-excipient interaction.
From the in vitro dissolution studies, it was observed that 
among the three different drug-polymer ratios used, 
formulations with drug-polymer ratio 1:1 showed higher 
drug release rates, when compared to 1:2 and 1:3. As the 
polymer concentration is increased, the drug release rates 
were found to be decreasing.  Higher drug release rates 
were observed for formulations with lower polymer ratio.  
An increase in polymer concentration causes increase in 
the viscosity of the gel as well as the formation of the gel 
layer with longer diffusional path.  This could cause a 
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decrease in effective diffusion coefficient of drug and 
therefore a reduction in drug release rate.  Among the 
three grades of polymers used, the tablets prepared with 
lower viscosity grade polymer i.e., HPMC K4M have 
shown greater drug release rates when compared to drug 
release rates of higher viscosity grade polymers HPMC 
K15M and K100M.
In all the formulations studied from F1 to F10 (Fig. 1), 
formulations containing HPMC K15M (F7) and K100M 
(F8) with drug-polymer ratio 1:3 containing cellactose as 
a diluent have shown sustained release of metoprolol 
tartrate up to 15 h.  Further to prolong the drug release up 
to 20 h, an attempt was made by incorporating Carbopol-
940 (release-modifying agent) in the formulations.
Formulations F9 and F10 containing drug-polymer ratio 
(1:3) with polymers composition of HPMC 
K15M:Carbopol-940 (2:1) in F9 and with polymers 
composition of HPMC K100M: Carbopol-940 (2:1) in 
F10 were prepared. The dissolution profiles of 
formulations shows that F9 and F10 have sustained the 
release of  drug  for more  than 20 h. The dissolution 
profiles of formulations containing HPMC and 
Carbopol-940 i.e., F9 and F10 have shown much slower 
release rates when compared to formulations containing 
HPMC alone i.e., F1 to F8.
The mechanism of drug release was studied using Peppas 
nequation, M /M =kt , where, M /M is fractional release of t t
the drug, 't' denotes the release time, K represents a 
constant incorporating structural and geometrical 
characteristics of the device, and n is the diffusional 
exponent and characterizes the type of release 
mechanism during the dissolution process.  For 
non–Fickian release, the n value falls between 0.45 and 
0.89, while in case of Fickian diffusion, n=0.45; for zero 
order release (case II transport), n=1, and for super case II 
7transport, n>1 . 
The values of n were estimated by linear regression of log 
(M /M) versus log (t) for different formulations and was t
found to be in between 0.45 to 0.89 indicating that 
diffusion is the predominant mechanism limiting the drug 
release. The formulations prepared were found to release 
the drug by non-Fickian transport (anomalous) since the 
slope values for Peppas plot were found to be in the range 
of 0.45 to 0.89 and also follows a near zero order release 
profile ('r' values for F9 and F10 formulations were found 
to be 0.984 and 0.994 respectively). From the above 
discussion, it may be concluded that HPMC along with 
Carbopol-940 can be used as an aid to control the delivery 
of water soluble drug from matrix tablets.  Among the 
various formulations of metoprolol tartrate developed, 
the formulations F9 and F10 appear suitable for further 
pharmacodynamic and pharmacokinetic evaluation in a 
suitable animal model.
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Ingredients (mg/tablet) 
FC Methocel Drug 
MT C-940 Cellactose  Talc MS Polymer:
K4M K15M K100M 
F1 50 50 -- -- -- 100 2 2 1:1 
F2 50 100 -- -- -- 50 2 2 1:2 
F3 50 -- 50 100 2 2 1:1 
F4 50 -- 100 -- -- 50 2 2 1:2 
F5 50 -- -- 50 -- 100 2 2 1:1
F6 50 -- -- 100 -- 50 2 2 1:2 
F7 50 -- 150  -- -- 50 2 2 1:3 
F8 50 -- -- 150  -- 50 2 2 1:3 
F9 50 -- 100 -- 50 50 2 2 1:2:1 
F10 50 -- -- 100 50 50 2 2 1:2:1
--
Table 1. Composition of various tablet formulations
FC: Formulation Code, MT: Metoprolol Tartrate, C-940: Carbopol-940, 
MS: Magnesium Stearate.
FC     
(kg/cm²)  (%)  (mg) (%) 
F1 5.80±0.76 0.64 202±0.42 99.72±0.52 
F2 5.90±0.51 0.62 200±0.25 98.10±3.00 
F3 5.60±0.59 0.63 199±0.87 97.10±1.53 
F4 5.90±0.49 0.59 202±0.92 97.50±2.51 
F5 5.80±0.34 0.62 200±0.32 96.78±2.08 
F6 5.80±0.51  0.64 201±0.60 96.32±1.41 
F7 5.60±0.42 0.66 243±2.55 98.62±0.60 
F8 5.80±0.67 0.63 249±0.08 99.36±0.28 
F9 5.90±0.37 0.61 254±1.46 99.60±0.20 
F10 5.70±0.49 0.67 249±0.66 99.60±0.76
a b c dHardness  Friability  Weight Variation  Drug Content  
Table 2. Physicochemical evaluation of matrix tablets of metoprolol tartrate
FC: Formulation code, a Mean ± S.D., n= 6 tablets, b  n= 10 tablets, c Mean ± S.D., 
n = 20 tablets and d Mean ± S.D., n=5 tablets,  SD: Standard Deviation.
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Fig. 1 : Drug release profiles of sustained release matrix 
tablets of Metoprolol Tartrate  (F 1 to F 10) formulations.
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Fl & F2: Drug -polymer ratio 1:1 & 1:2 using HPMC 
K4M Polymer
F3 &F4: Drug -polymer ratio 1:1 & 1:2 using HPMC 
K15M Polymer
F5 & F6: Drug -polymer ratio 1:1 & 1:2 using HPMC 
KI00M Polymer
F7 & F8: Drug -polymer ratio 1:3 using HPMC K15M & 
KI00M Polymer
F9&FI0: Drug -polymer ratio 1:3 with polymers 
composition of HPMC K15M : Carbopol-940 (2: 1) in F9 
and with polymers composition of HPMC KI00M: 
Carbopol-940 (2:1) in F10
